[Ramipril in the treatment of hypertension. The pharmacodynamic validation of its efficacy in the therapy of initial cardiac and renal involvement].

A clinical trial of 75 hypertensive subjects in stage II of the disease receiving ramipril monotherapy has established a marked efficacy of the above treatment. Individually adjusted single doses varied from 2.5 mg to 7.

[The specificity of the hypotensive effect of calcium antagonists in hypertension].

The purpose of the study was to define prognostic criteria that determine individual sensitivity to the hypotensive effect of slow calcium channel blockers. After two weeks of placebo therapy 45 patients suffering from essential hypertension underwent an acute pharmacological test (APT) with nifedipine in a dose of 30 mg. Then the patients received monotherapy with nitrendipine in the increasing doses for 12 weeks.